Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

February 23, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Head and Neck CancerOropharynx CancerHuman Papilloma Virus
Interventions
RADIATION

SABR boost and de-escalated chemoradiation

Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions

RADIATION

Standard chemoradiation

Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions

Trial Locations (2)

Unknown

RECRUITING

London Health Sciences Center, London

H2X 1R6

RECRUITING

Centre Hospitalier de l'Université de Montréal, Montreal

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

collaborator

Jewish General Hospital

OTHER

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT04178174 - Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer | Biotech Hunter | Biotech Hunter